Navigation Links
Genelabs Technologies to Present at the BIO CEO & Investor Conference
Date:2/7/2008

REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that its Chief Financial Officer Fred Driscoll will present a company update at the BIO CEO Investor Conference at the Waldorf Astoria Hotel Tuesday, February 12, 2008 at 2:00 pm E.T.

The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at http://www.genelabs.com or through the following URL: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=GNLB&item_id=17523 37 The presentation will also be available for replay after the presentation for a limited time.

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program. We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit http://www.genelabs.com.

Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.

Contact: Frederick W. Driscoll

Chief Financial Officer

Phone: 650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genelabs Technologies, Inc. Announces Resignation of President and CEO
2. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
3. Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions
4. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
5. Guava Technologies Celebrates Tenth Anniversary
6. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
7. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
8. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
11. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a ... announce development of a novel system for quantitative ... with the University of Rochester (NY, USA) and ... The new system is able to accurately quantify ... HER2 (Human epidermal growth factor receptor-2) in clinical ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a ... held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers ... an opportunity to interact with peers, make new connections and talk bio biz. , ...
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
Breaking Biology News(10 mins):